Journal Article10.1016/S0016-5085(17)32487-3
Linaclotide is Effective and Safe for Patients with Irritable Bowel Syndrome with Constipation in Japan: A Phase III Randomized, Double-Blind, and Placebo-Controlled and Long-Term Extension Study
Shin Fukudo,Hiroto Miwa,Atsushi Nakajima,Ken Haruma,Masanori Kosako,Ayako Nakagawa,Hiraku Akiho,Yusuke Yamaguchi,Jeffrey M. Johnston,Mark G. Currie,Yoshikazu Kinoshita +10 more
2
About: This article is published in Gastroenterology. The article was published on 01 Apr 2017. The article focuses on the topics: Linaclotide & Constipation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
New treatments and therapeutic targets for IBS and other functional bowel disorders.
Magnus Simrén,Jan Tack +1 more
TL;DR: New drugs for FBDs target key pathophysiological mechanisms and differ from current therapies by improving the abnormal bowel habit as well as other symptoms, such as abdominal pain and bloating.
125
Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
Shin Fukudo,Hiroto Miwa,Atsushi Nakajima,Yoshikazu Kinoshita,Masanori Kosako,Ayako Nakagawa,Hiraku Akiho,Kentaro Kuroishi,Jeffrey M. Johnston,Mark G. Currie,Toshifumi Ohkusa +10 more
TL;DR: This phase II/III studies of irritable bowel syndrome with constipation in Japan demonstrated the efficacy and safety of linaclotide 0.5 mg/d and lower in the treatment of patients with chronic constipation.
17